↓ Skip to main content

Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy

Overview of attention for article published in Frontiers in immunology, October 2023
Altmetric Badge

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
11 Mendeley